LOX-1, an Oxidized Low-Density Lipoprotein Receptor, Was Upregulated in the Kidneys of Chronic Renal Failure Rats.
スポンサーリンク
概要
- 論文の詳細を見る
<B>LOX-1 is a novel receptor for oxidized low-density lipoprotein (LDL) isolated from vascular endothelial cells and has been suggested to be involved in the formation of atherosclerotic and hypertensive vascular lesions. We previously reported that salt loading caused glomerulosclerosis and upregulation of LOX-1 in the kidney of Dahl salt-sensitive hypertensive rats. In the present study, we investigated LOX-1 expression in the remnant kidney, an established rat model for chronic renal failure. Six weeks after 5/6 nephrectomy, the rats showed elevated blood pressure, impaired renal function and increased renal expression of type I collagen. The LOX-1 gene expression in the remnant kidney was markedly increased compared with that in control rats, and immunohistochemical analysis showed that LOX-1 was widely expressed in the interstitial cells, whereas there was almost no staining in the glomeruli or tubules. Moreover, reduction of blood pressure by the angiotensin II type 1 (AT1) receptor antagonist candesartan significantly suppressed the renal LOX-1 expression, and this suppression was accompanied by amelioration of renal injury. These results suggest that enhanced renal expression of LOX-1 might play some roles in the progression of chronic renal failure in rats. (<I>Hypertens Res</I> 2003; 26: 117-122)</B>
- 日本高血圧学会の論文
日本高血圧学会 | 論文
- Telmisartan treatment decreases Visceral Fat Accumulation and improves Serum Levels of Adiponectin and Vascular Inflammation Markers in Japanese Hypertensive Patients.
- The Effects of Verapamil SR and Bisoprolol on Reducing the Sympathetic Nervous System's Activity.
- The Role of Renal Dopamine in the Reduction of High Blood Pressure by β1-Selective β-Blocker with Intrinsic Sympathomimetic Activity in Spontaneously Hypertensive Rats
- Effects of Long-Term Antihypertensive Therapy on Physical Fitness of Men with Mild Hypertension.
- Prediction of Progression of Left Ventricular Hypertrophy in Mild Hypertension: 5-Year Observations without Pharmacological Intervention.